Diazepam Oral Solution Recalled for Failed Impurity Specifications
Lannett Company is recalling Diazepam Oral Solution (Concentrate) 5 mg/mL due to out-of-specification results for related substances, indicating failed impurities and degradation testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving a drug quality defect (failed impurity/degradation specifications). No illnesses or injuries are reported in the source text. Per the rubric, Class II recalls with no reported hospitalization or injury are typically scored as 2 (Moderate).
Plain-English summary
Lannett Company, Inc. is recalling Diazepam Oral Solution (Concentrate), 25 mg per 5 mL (5 mg/mL), in 30 mL bottles with dropper, NDC 0527-1768-36. The recall affects approximately 23,598 bottles that were distributed nationwide in the USA.
The recall was initiated because testing identified out-of-specification results for related substances, indicating that the product failed impurities and degradation specifications.
Affected lots are: Lot #2664A, Lot #2664B (expiration date 07/2022), and Lot #2874A, Lot #2874B (expiration date 01/2023).
Patients taking this medication should consult their healthcare provider or pharmacist about the recall. Individuals with questions may contact Lannett Company, Inc.
The recalled product
- Product
- Diazepam Oral Solution (Concentrate), 25 mg per 5 mL (5 mg/mL), 30 mL BOTTLE and DROPPER, Rx Only, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136, NDC 0527-1768-36.
- Manufacturer
- Lannett Company, Inc.
- Affected units
- 23,598
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: 2664A
- 2664B
- Exp. date 07/2022
- 2874A
- 2874B
- Exp. date 01/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Lannett Company, Inc.
See all →- HighAmphetamine extended-release capsules contain immediate-release pellets after label mix-up
FDA (Drugs) · 2026-07-08
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateNiacin extended release tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-29
- HighAmphetamine salt tablets recalled after bottles contained a lower strength tablet
FDA (Drugs) · 2025-09-17
Same hazard · impurity degradation
See all →- Low
- ModerateEsomeprazole Magnesium oral suspension recalled for failed impurity specifications
FDA (Drugs) · 2025-05-28
- HighDiltiazem Hydrochloride extended-release capsules recalled due to failed quality specifications
FDA (Drugs) · 2023-02-08
- ModerateXiidra ophthalmic solution recalled for failed impurity and degradation specifications
FDA (Drugs) · 2022-06-15
- ModerateXiidra Ophthalmic Solution Recalled for Failed Impurity and Degradation Specifications
FDA (Drugs) · 2022-06-15